Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers
Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers
复制标题
DOI：
10.2217/fon-2016-0566
复制
发表时间：
2017-06-01
期刊：
影响因子：
3.3
通讯作者：
MacLean, Elizabeth A.
中科院分区：
文献类型：
--
作者：
Hutson, Thomas E.;Jiao, Xiaolong;MacLean, Elizabeth A.
目的：研究真实世界中阿西替尼用于转移性肾细胞癌的患者特征和治疗模式。患者和方法：我们使用美国肿瘤学网络数据库，对2012年1月1日至2014年10月31日期间135例转移性肾细胞癌患者中二线或三线阿西替尼的使用情况进行了回顾性分析。结果：总体而言，86.7%的透明细胞组织学，57.8%的诊断为III/IV期疾病，55.6%的Heng标准为低风险。中位治疗持续时间为4.6个月（范围：0.03-35.49）; 80.7%的患者开始接受5 mg/天的阿昔替尼治疗，每日两次，67.4%的患者维持该剂量。总体而言，77.8%的患者停止治疗，主要是由于疾病进展（50.5%）和毒性（21.9%）。结论：阿西替尼的使用模式与国家综合癌症网络指南（R）一致。社区肿瘤学家的易用性和患者的耐受性是阿西替尼的关键特征。
Aim: To study patient characteristics and treatment patterns in real-world axitinib use for metastatic renal cell carcinoma. Patients & methods: We conducted a retrospective analysis of second- or third-line axitinib use between 1 January 2012 and 31 October 2014 in 135 metastatic renal cell carcinoma patients using the US Oncology Network database. Results: Overall, 86.7% had clear cell histology, 57.8% had stage III/IV disease at diagnosis and 55.6% were poor risk by Heng criteria. Median treatment duration was 4.6 months (range: 0.03-35.49); 80.7% initiated axitinib at 5 mg/day twice daily, and 67.4% maintained this dose. Overall, 77.8% discontinued treatment, mainly due to disease progression (50.5%) and toxicity (21.9%). Conclusion: Axitinib usage patterns were consistent with the National Comprehensive Cancer Network Guidelines (R). Ease of use among community oncologists and patient tolerance are key features of axitinib.